StreetAlpha.app
Home › Stocks › OKUR

OnKure Therapeutics, Inc. (OKUR)

Healthcare
$2.70
▼ −2.17%
LAST CLOSE · NOV 20

OnKure Therapeutics develops small molecule drugs that target mutated forms of the PI3K alpha protein in cancer and other diseases. It last closed at $2.70 on Nov 20, down 2.17% on the day. The next earnings report for OKUR is expected around Thu, Mar 11, 2027, after the close. For the quarter ended Sep 2026, OKUR reported EPS of -$0.36 on revenue of $1.5M, with revenue up 87.7% from a year ago. Over its last 8 reports the stock moved an average of 7.5% the session after earnings. Over the last 12 months OKUR insiders bought $0 of stock on the open market and sold $6K, according to SEC Form 4 filings.

AI Auto Pilots
Is OKUR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold OKUR.

Key Stats

Last 12 months
Results
Revenue
$4.1M
+1.7% vs a year ago
Net income
−$61.9M
−1494.7% margin
EPS (diluted)
−$2.26
−102.4% vs a year ago
Free cash flow
−$47.9M
−1158.4% margin
Valuation
Market cap
$109.4M
40.5M shares
P/E
–
No P/E while losing money
Price to sales
26.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$151.4M
At Sep 30
Shareholder equity
$157.7M
Shares outstanding
40.5M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $1.6M$1.6MFY2023FY2024: $1.7M$1.7MFY2024FY2025: $3.4M$3.4MFY2025

From OKUR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Mar 11
Estimated date · After the close
Reported EPS
-$0.36
Quarter ended Sep 2026
Year ago EPS
-$1.09
Same quarter last year
Revenue
$1.5M
+87.7% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $96.49Dec '24Mar 2025: -$1.19Mar '25Jun 2025: -$1.14Jun '25Sep 2025: -$1.09Sep '25Dec 2025: -$0.99Dec '25Mar 2026: -$1.11Mar '26Jun 2026: -$0.31Jun '26Sep 2026: -$0.36Sep '26Latest -$0.36
Revenue by quarter
Dec 2024: $1.3MDec '24Mar 2025: $1.1MMar '25Jun 2025: $934,000Jun '25Sep 2025: $802,000Sep '25Dec 2025: $622,000Dec '25Mar 2026: $458,000Mar '26Jun 2026: $1.6MJun '26Sep 2026: $1.5MSep '26Latest $1.5M
How OKUR moved after its last 8 reports
Average move the session after a report ±7.5%
Nov 4, 2026After the close−2.5%
Aug 4, 2026After the close+1.5%
May 5, 2026After the close−10.0%
Mar 12, 2026After the close+7.4%
Nov 6, 2025After the close−7.0%
Aug 12, 2025After the close+20.0%
May 6, 2025Time not announced−11.2%
Mar 10, 2025After the close−0.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on OKURStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on OKUR
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on OKUR

Technical Analysis

OKUR · as of the Nov 20 close · updated each morning
Bounce inside a longer downtrend

The stock sits between its 20 and 50 day averages. It is 34% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 49). The nearest support is the 50 day average at $2.67, and the nearest resistance the swing high (Oct 27) at $2.72.

Short trendBullish
Long trendBearish
MomentumFading
StretchNormal
VolatilityHigh, 10.3%/day
Key levels
$5.3852 week high+99.3%
$3.62200 day average+34.1%
$3.33100 day average+23.3%
$2.78Pivot R1+3.0%
$2.7620 day average+2.2%
$2.73Pivot+1.1%
$2.72Swing high (Oct 27)+0.7%
$2.70Last close
$2.6750 day average−1.1%
$2.65Pivot S1−1.9%
$2.50Swing low (Nov 17)−7.4%
$2.0152 week low−25.6%
Indicators
RSI (14)48.71Middle of its rangeNeutral
MACD0.03Below its signal lineBearish
Stochastic35.2Middle of its rangeNeutral
ADX (14)13.7No clear trend
Williams %R-69.5Oversold below −80, overbought above −20Neutral
CCI (20)-5.2Oversold below −100, overbought above 100Neutral
Rate of change−5.8%Change over 10 sessionsBearish
ATR (14)$0.28Typical daily range, 10.3% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Below
MA 200Below
What happened before, for OKUR

What happened before

See how OKUR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow OKUR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How OKUR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for OKURHow many large options trades hit OKUR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

OKUR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲44 buying vs 20 selling
  • ▲Held by funds +1.2 pts
  • ▲Funds holding +8
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding8375+10.7%
In funds' top 10220.0%
Held by funds87.5%86.3%+1.2 pts
New / increased12 / 3231 / 21−15.4%
Reduced / sold out16 / 49 / 8+17.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OKUR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

OKUR Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$6K8 sales · 2 insiders
2025-12 sold $1K2026-03 sold $2K2026-06 sold $2K2026-09 sold $1KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 21Nicholas A SaccomanoPresident and CEOSale87$2.97$259
Sep 21Jason A. LeveroneCFOSale302$2.97$898
Jun 22Nicholas A SaccomanoPresident and CEOSale86$4.40$378
Jun 22Jason A. LeveroneCFOSale303$4.40$1K
Mar 23Nicholas A SaccomanoPresident and CEOSale86$4.16$358
Mar 23Jason A. LeveroneCFOSale301$4.16$1K
Every insider buy and sale for OKUR over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See OKUR insider trades →

From SEC Form 4 filings by OKUR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OKUR is in one of them and how their past OKUR trades turned out.

OKUR in the AI portfolios
Loading…

OKUR News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OKUR in an article yet. Here's the latest on the wider market.

OKUR in the news

About OnKure Therapeutics

OnKure Therapeutics is a biopharmaceutical company based in Boulder, Colorado. It develops small molecule drugs that target specific mutated forms of the PI3K alpha protein, a driver of cancer and other diseases, while sparing the normal form of the protein. Its lead candidate, OKI-219, is in Phase 1 clinical trials for patients with advanced breast cancer, and the company is also researching treatments for vascular malformations.

Headquarters
Boulder, CO